BARBA, MADDALENA
 Distribuzione geografica
Continente #
NA - Nord America 1.001
EU - Europa 505
AS - Asia 141
AF - Africa 7
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.658
Nazione #
US - Stati Uniti d'America 988
SE - Svezia 264
IT - Italia 109
SG - Singapore 65
IN - India 47
FI - Finlandia 36
DE - Germania 31
GB - Regno Unito 20
CN - Cina 16
IE - Irlanda 14
CA - Canada 11
BG - Bulgaria 9
RO - Romania 7
FR - Francia 5
IR - Iran 5
TG - Togo 5
HK - Hong Kong 4
CH - Svizzera 3
UA - Ucraina 3
NL - Olanda 2
TH - Thailandia 2
AR - Argentina 1
CL - Cile 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
EU - Europa 1
GR - Grecia 1
ID - Indonesia 1
JP - Giappone 1
MX - Messico 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 1.658
Città #
Fairfield 163
Stockholm 154
Ashburn 74
Seattle 68
Cambridge 66
Chandler 61
Houston 59
Woodbridge 54
Wilmington 50
Singapore 36
Rome 33
Helsinki 32
Princeton 30
Dearborn 26
New York 22
San Paolo di Civitate 22
Millbury 17
Ann Arbor 15
Lawrence 15
Sacramento 14
Bremen 13
Dublin 12
San Diego 12
Andover 11
Plano 10
Sofia 9
Ottawa 8
Surrey 7
Boardman 6
Boston 6
Norwalk 6
Santa Clara 6
Beijing 5
Bühl 5
Lomé 5
Los Angeles 5
Hong Kong 4
Milan 4
Dallas 3
Glasgow 3
Guangzhou 3
Torino 3
Birmingham 2
Bovisio-Masciago 2
Falls Church 2
Fort Worth 2
Leawood 2
Liverpool 2
Livorno 2
Magenta 2
Mannheim 2
Palermo 2
Phoenix 2
Redwood City 2
Shenyang 2
Toronto 2
Trumbull 2
Zanjan 2
Augusta 1
Bangkok 1
Berlin 1
Bern 1
Buffalo 1
Cadelbosco di Sopra 1
Catania 1
Corridonia 1
Edinburgh 1
Falkenstein 1
Federal 1
Frattamaggiore 1
Fremont 1
Frosinone 1
Fuzhou 1
Groningen 1
Guayaquil 1
Guidonia 1
Guidonia Montecelio 1
Hefei 1
Henderson 1
Indore 1
Kashan 1
Kish 1
Lappeenranta 1
Levallois-perret 1
Menlo Park 1
Muizenberg 1
Naples 1
Padova 1
Quzhou 1
Riva 1
San Mateo 1
Santiago Metropolitan 1
Shanghai 1
Southend 1
Springfield 1
Tallinn 1
Thessaloniki 1
Treviso 1
Vigonza 1
Winnipeg 1
Totale 1.231
Nome #
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 184
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 120
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 105
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 97
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study 97
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer 91
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients 81
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 76
Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial 70
Autoantibodies specific to ERa are involved in tamoxifen resistance in hormone receptor positive breast cancer 64
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 61
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 60
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 60
null 54
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials 54
null 52
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 50
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience 43
null 39
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 38
Observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. Outline of the arias trial 37
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives 34
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer 28
Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists 23
Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration 22
null 21
Prognostic relevance of neutrophil to lymphocyte ratio (Nlr) in luminal breast cancer: A retrospective analysis in the neoadjuvant setting 20
Neoadjuvant endocrine therapy in breast cancer. Current knowledge and future perspectives 20
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 18
How Dual-Energy Contrast-Enhanced Spectral Mammography Can Provide Useful Clinical Information About Prognostic Factors in Breast Cancer Patients: A Systematic Review of Literature 18
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer 16
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 15
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 15
Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors 13
Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer: A hypothesis-generating study 12
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study 10
Breast and cervical cancer in transgender men: literature review and a case report 1
Totale 1.819
Categoria #
all - tutte 5.959
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.959


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020293 0 0 0 10 38 51 47 41 43 29 19 15
2020/2021152 24 9 8 9 4 11 0 5 13 54 12 3
2021/2022324 3 5 15 18 63 23 4 23 12 20 93 45
2022/2023397 85 67 28 27 54 35 14 38 27 8 10 4
2023/2024215 6 24 12 18 26 32 1 37 5 23 22 9
2024/2025254 166 40 42 6 0 0 0 0 0 0 0 0
Totale 1.819